New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
07:31 EDTALIMAlimera Sciences receives positive outcome for Iluvien in procedure
Alimera Sciences announced the positive outcome of the Repeat-Use Procedure for ILUVIEN for the treatment of chronic diabetic macular edema in an additional 10 European Union countries. Alimera submitted the application through the Mutual Recognition Procedure with the Medicines and Healthcare products Regulatory Agency of the United Kingdom serving as the Reference Member State. The regulatory process for these additional countries, consisting of Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland and the Czech Republic, will now enter the national phase in which each country grants marketing authorization. ILUVIEN will be indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.
News For ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
07:37 EDTALIMAlimera Sciences signs exclusive agreement for distribution of Iluvien in Canada
Alimera Sciences announced that it has signed an exclusive agreement with Knight Therapeutics, a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use